Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | CCR8 | P51685 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29060953 | 0.82 | ABCB1 (0.35) | KDM4EPSMD14COPS5ABCB1ABCG2 | |
| SCHEMBL4548616 | 0.81 | KDM4E (0.39) | KDM4EPSMD14COPS5SLC40A1CCR1 | |
| SCHEMBL21657612 | 0.81 | KDM4E (0.42) | KDM4EPSMD14COPS5SLC40A1CCR1 | |
| SCHEMBL23478918 | 0.79 | PTPN6 (0.38) | KDM4EPSMD14COPS5SLC40A1CCR1 | |
| SCHEMBL14327674 | 0.79 | CCR1 (0.52) | KDM4EPSMD14COPS5ALOX5APCCR1 | |
| SCHEMBL24721913 | 0.77 | PSMD14 (0.39) | KDM4EPSMD14COPS5CCR1CCR5 | |
| SCHEMBL13222348 | 0.77 | HPGDS (0.57) | KDM4ENPC1 | |
| SCHEMBL3718782 | 0.77 | KDM4E (0.62) | KDM4EPSMD14COPS5ABCB1ABCG2 | |
| SCHEMBL20509073 | 0.76 | PARP1 (0.42) | KDM4EPSMD14COPS5PARP1 | |
| SCHEMBL4819023 | 0.76 | CCR1 (0.42) | KDM4EPSMD14COPS5SLC40A1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230321049-A1 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | Petragen, Inc. | 2023-10-12 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321049-A1 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | KDM4E 4063/4885PSMD14 3687/4885COPS5 1732/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | KDM4E 4019/4885PSMD14 1582/4885COPS5 2080/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | KDM4E 4019/4885PSMD14 1582/4885COPS5 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.